Sign in / Join Now
ETFs & Funds
done nothing wrong for this drop. Everystocks were pulled down. SRPT is not a risky asset for now. FDA is getting more pressure as
it delays on the accelerated approval on the drug. And it's getting more public attention than before;
Add a reply...
Latest StockTalks »
people get SRPT breaking news and analysis by email alert.
Get email alerts on SRPT »
Sarepta Therapeutics, Inc.
Get latest price
From other sites
Sarepta Therapeutics To Announce Third Quarter 2016 Financial Results And Recent Corporate Developments On October 27, 2016
at TheStreet (Mon, 8:30AM)
For Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform
at Benzinga (Oct 18, 2016)
Exclusive: SunTrust Managing Director Goes Over Sarepta Therapeutics' Story
at Benzinga (Oct 17, 2016)
Short Interest In Sarepta Therapeutics Moves 21% Lower
at Nasdaq.com (Oct 13, 2016)
Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51
at Benzinga (Oct 10, 2016)